Weekly Medical Device News Roundup (June 22–28, 2026): Regulatory Approvals, Strategic Partnerships, and IPO Filings

Recently, the Jinan Municipal Government responded to proposals from the Provincial Committee of the Chinese People's Political Consultative Conference (CPPCC), outlining the progress and plans for the National Health and Medical Big Data Northern Center. In recent years, Jinan has actively promoted the development of "Digital Intelligence Jinan," achieving significant results in supporting the construction of the Northern Center: aggregating massive data resources, launching ten major application scenarios, completing the first compliant data transaction, and forming the first batch of high-quality datasets; advancing the construction of supporting facilities, expanding physical space, enhancing data storage and computing power support capabilities, and implementing functions such as cloud-based imaging storage; establishing advanced operational models, building data training bases, exploring sector-specific authorized operations, and completing the organization of public data resources, thereby improving the experience of medical treatment and settlement. Moving forward, Jinan will support the upgrade of the Northern Center to a national-level center, cooperate in optimizing computing power layout and storage capabilities, and strive to establish a national pilot base for artificial intelligence applications in "AI + Elderly Care and Health."

Recently, Sinopharm Medical Device Strategic Product Operations Center (Shanghai Company) held a strategic cooperation symposium in the coronary field with Shanghai MicroPort Medical (Group) Co., Ltd. and signed an agreement. Dang Tiefei, Deputy General Manager of Sinopharm Medical Device, Yue Bin, President of MicroPort Medical, and other executives attended the meeting. Dang Tiefei expressed his hope to deepen cooperation to benefit more patients with MicroPort products, while Yue Bin stated that they would fully promote the collaboration. During the meeting, Zheng Yan, General Manager of Sinopharm Medical Device Strategic Product Operations Center (Shanghai Company), interpreted the "Three Ones" development goals and proposed multiple cooperation measures. Sun Congcong, Vice President of China Coronary Promotion and Treatment Solutions at MicroPort Medical, introduced the development of MicroPort's coronary business and stated that they would advance the substitution of domestic products in the medical field. After the meeting, both parties engaged in in-depth discussions on the details of local cooperation. This symposium marks a new stage in the strategic partnership between the two sides. The Sinopharm Medical Device Strategic Product Operations Center will accelerate the nationwide implementation of strategic products to promote high-quality development.

Recently, Yashoda Medical City and GE HealthCare are exploring opportunities to advance AI-driven critical care services by integrating advanced diagnostic technologies and digital health solutions. The proposed collaboration aims to strengthen clinical decision-making, improve patient monitoring, and enhance treatment outcomes in critical care settings. Furthermore, this partnership reflects the increasingly widespread application of artificial intelligence and remote monitoring technologies in the healthcare sector. AI-powered command centers are being increasingly utilized to support critical care teams by providing continuous patient monitoring, predictive analytics, and early warning alerts, thereby facilitating the timely identification of risks before clinical deterioration becomes life-threatening.

Shanxi Provincial Drug Administration Holds Risk Assessment Meeting on Medical Devices, Proposing Strengthened Supervision of Their Distribution and Use Across the ProvinceRecently, the Shanxi Provincial Drug Administration convened a risk assessment meeting on medical devices, proposing enhanced supervision of their distribution and use throughout the province. The meeting reported current risks in the distribution and use stages, analyzed regulatory shortcomings, and outlined tasks for the next phase: All localities are to focus on key priorities, strictly uphold safety baselines, and concentrate on critical areas such as products selected through centralized procurement and myopia prevention and control among adolescents. Risk registers shall be established to ensure closed-loop risk management. Supervisory inspections must be strengthened, with severe crackdowns on illegal activities such as unlicensed operations, leveraging the public exposure of typical cases to create a deterrent effect. Furthermore, local territorial supervisory responsibilities and corporate principal responsibilities must be further consolidated to build a collaborative regulatory framework. Training for grassroots regulatory personnel should be enhanced to improve capabilities in risk identification and disposal, thereby providing a solid guarantee for promoting standardized and orderly development in the distribution and use of medical devices across the province.

The FDA Announces the Downclassification of Numerous Medical Devices to Class II (Special Controls). The affected devices include: external lower extremity nerve stimulators for the treatment of restless legs syndrome, computerized behavioral therapy devices for the treatment of fibromyalgia symptoms, SARS-CoV-2 serological tests, infant supine sleep systems, foam or gel chemical sterilants/high-level disinfectants, breast implant aspiration removal systems, and prognostic tests for diagnosing the onset or progression of preeclampsia.